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Characteristics of Acute Care Utilization of a Delaware
Adult Sickle Cell Disease Patient Population
Nina Anderson, DNP, RN, FNP-BC,1 Jennifer Bellot, PhD, RN, MHSA,1
Oluseyi Senu-Oke, MD,2 and Samir K. Ballas, MD3
Abstract
Sickle cell disease (SCD) is an inherited blood disorder that is chronic in nature and manifests itself through
many facets of the patient’s life. Comprehensive specialty centers have the potential to reduce health care costs
and improve the quality of care for patients who have chronic medical conditions such as heart failure and SCD.
The purpose of this practice inquiry was to analyze de-identified data for acute care episodes involving SCD in
order to create a detailed picture of acute care utilization for adult patients in Delaware with SCD from 2007 to
2009. Gaining a better understanding of acute care utilization for adults with SCD may provide evidence to
improve access to high-quality health care services for this vulnerable patient population in the state of Dela-
ware. (Population Health Management 2014;17:60–65)
Introduction
The challenges of managing patients with complexchronic conditions, such as adults with sickle cell disease
(SCD), call for an exploratory analysis of acute care utilization
for adults with SCD in Delaware. Understanding the land-
scape of acute care visits can inform a strategic plan of action
to improve access to high-quality care services and reduce
overall health care expenditures for these patients. SCD pri-
marily affects people of African descent, and the sickle gene
mutation is prevalent in the Caribbean, Mediterranean, In-
dian, and other geographic regions in which malaria is also
prevalent. Under conditions of deoxygenation of the sickle
hemoglobin, red blood cells sickle and change shape, leading
to vaso-occlusion that deprives body tissues and organs of
needed circulation and oxygenation. This causes excruciating
pain that, over time, can damage the blood vessels and major
organs.1
SCD is associated with significant morbidity and mortal-
ity. Medical complications associated with the disease in-
clude: stroke, retinopathy, pulmonary hypertension, chronic
pain, avascular necrosis of the hips and shoulders, leg ulcers,
increased vulnerability to infections, blood transfusion reac-
tions, alloimmunization, multiorgan damage (lungs, kid-
neys, spleen), psychological distress, depression, substance
abuse, and opioid tolerance or dependency. Nonmedical
complications include unemployment, lack of education and
vocational training, lack of transportation, and disability
(S.K. Ballas, MD, unpublished data, October 2011; O. Senu-
Oke, MD, unpublished data, June 2011).
Significance
As the population ages and US health care changes be-
cause of implementation of the Patient Protection and Af-
fordable Care Act, there are major implications to address
the fundamental infrastructure for providing comprehensive
specialty care and services for patients with complex chronic
medical conditions. SCD is a chronic medical condition that
incurs a significant cost burden for the care of adult patients.
The total annual prorated fees (assuming a 6% inflation in-
crease per year) for an adult SCD patient were estimated at
$725,037 in 2008; it is estimated that the total undiscounted
costs (SCD-related and non-SCD-related) could reach
$953,640 for a person reaching 45 years of age.2,3 The man-
agement of SCD can become costly because of the chronicity
and the recurrence of exacerbations.
SCD Landscape in Delaware
Children with SCD in the state of Delaware have access to
a comprehensive sickle cell program at a large pediatric
hospital, which also has a satellite clinic in Sussex County.
Once a patient reaches adulthood and must transition out of
the pediatric program (between ages 18 to 21 years), there is
1Jefferson School of Nursing, Philadelphia, Pennsylvania.
2Delaware Physicians Associates, Wilmington, Delaware.
3Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania.
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no adult comprehensive specialty center in Delaware to
provide patients with continued high-quality, patient-
centered care by their primary care provider or hematologist,
including psychosocial support and resources for this vul-
nerable patient population. In the surrounding geographic
area (ie, New Jersey, Pennsylvania, Maryland), Delaware is
the only state that does not provide funding for an adult
comprehensive specialty SCD center. For this reason, SCD
care and management may be subject to fragmentation, less
coordination, and increased utilization of acute care services.
Epidemiology
Approximately 100,000 people (1 in every 500 African
American births) in the United States live with SCD. Over
2.5 million people (1 in 12 people) of African descent carry
the trait. People of Hispanic descent are the fastest growing
ethnic group in the United States with SCD. It is estimated
that over 750 people in the state of Delaware live with SCD,
more than 350 of whom are adults (18 years of age and older)
(O. Senu-Oke, MD, unpublished data, June 2011).4–6
Purpose
The purpose of this practice inquiry (PI) was to analyze
de-identified data for acute care episodes involving SCD in
order to create a detailed picture of acute care utilization for
adult patients in Delaware with SCD from 2007 to 2009. The
aim of this PI was to determine the characteristics of acute
care utilization, health care expenditures, and acute care
costs for adult SCD patients in order to determine whether a
comprehensive adult SCD specialty care is needed in
Delaware.
Literature review
A review of the literature included a search of PubMed,
Scopus, and CINAHL databases. Articles examined ad-
dressed the barriers for adults with SCD, hospital read-
mission within 30 days, and costs to provide care for adult
SCD patients. The findings from the articles were further
reviewed and critiqued for content, sorted by topic, and
synthesized to find evidence to inform the PI.
Costs. The Healthcare Cost and Utilization Project
(HCUP) examined the characteristics of 113,098 SCD hospi-
talizations of adults and children nationwide from 1994 to
2004. The number of SCD-related hospitalizations for adults
in 2004 remained statistically unchanged at 83,149 per year,
equivalent to the number of hospitalizations in 1997. A large
percentage of hospital admissions for SCD (75%) came via
the emergency room (ER) in 2004. Approximately two thirds
of the adult SCD patients hospitalized were 18–44 years of
age; 31% received a blood transfusion, 25% had an infection,
14% had a pulmonary condition, and 18% had a substance-
related or other mental health disorder. More than 75% of all
hospital patient stays for adults and children were billed to
Medicare or Medicaid. In 2004, the total hospital costs for all
SCD patients reached $488 million; average cost per hospital
stay was $6223.7
Kauf et al examined the estimated cost of care for 4294
adults and children with SCD.3 The study found that more
than 80% of SCD-related costs for Florida Medicaid patients
during 2001–2005 were associated with acute care and ER
visits, and only 1% was associated with outpatient physician
visits. The median lifetime discounted and undiscounted
costs (SCD-related and non-SCD-related) were estimated to
be between $186,406 and $392,940. Lanzkron et al also ex-
amined the costs of adult SCD care using Maryland Hospital
Discharge Data collected from fiscal year (FY) 1995 to
FY2003.8 The hospitalization costs increased from $9.8 million
in FY1995 to $15.6 million in FY2003 (P < 0.001). The
total costs for inpatient adult SCD care were 60% higher,
even after adjusting for inflation (producer price index)
during the years of data analysis. Woods et al examined
hospital utilization patterns of 1189 adult SCD patients in
Illinois in 1992 and 1993.9 The total charges for adult SCD
hospital admissions during the 2-year study period were
over $59 million, or approximately $30 million per year. The
most common admitting diagnosis was for vaso-occlusive
pain crisis (97.4%); a large majority of patients (85.7%) were
admitted through the ER.9
Further, national estimates of ER utilization for 50,418
SCD-related ER visits were analyzed from the Nationwide
Emergency Department Sample in 2006. The study found
that combined overall costs for ER and hospital visits for
children and adults with SCD were $2.4 billion, which is a
significant cost burden.10 A study found that SCD patients in
Alabama who were enrolled in a comprehensive specialty
SCD clinic used the ER and were hospitalized less frequently
than those patients who were not enrolled in the clinic. The
33.5% of these patients who did not utilize services at spe-
cialty clinics constituted 71.4% of ER visits and 42.3% of
hospital admissions.11 There was a significant reduction in
the total cost of care for patients who attended these clinics.
Hospital readmissions. Ballas and Lusardi examined
hospital admissions for adults with SCD hemoglobin SS-type
(SCD-SS) from 1998 to 2002 at Thomas Jefferson University
Hospital in Philadelphia, Pennsylvania.12 One hundred
eighty-two patients with SCD-SS type were followed pro-
spectively and longitudinally for hospital discharge patterns.
The results revealed that 136 patients were admitted 1540
times with an average length of stay (LOS) of 7.6 days. There
were 228 (16%) readmissions within 1 week of discharge,
and 726 (50%) readmissions within 1 month of discharge.
Readmissions were more frequent for males (70%) than fe-
males. Pain intensity scores in the severe range at discharge
increased the risk of hospital readmission. Characteristics of
narcotic withdrawal symptoms were reported by 55 patients
who were readmitted within 1 week, and 78 patients who
were readmitted within 1 month of hospital discharge. A
retrospective cohort study by Brousseau et al found SCD-
related 30-day rehospitalization rates in 8 geographically
dispersed states to be 33% for all ages.13 The study also
found that hospital readmission within 14 days of a previous
admission was 28%, and that the 30-day hospital read-
mission rate was highest for adult SCD patients ages 18–30
years (41%). The 7-day hospital readmission rate was not
reported in this study. Overall, hospital readmissions were
highest for patients who were publicly insured.
Another study examined the risk factors for hospital
readmissions within 30 days of discharge for children with
SCD at a St. Louis, Missouri hospital during 2005–2006. Of
the 105 SCD patients meeting inclusionary criteria, 30 were
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readmitted within 30 days of discharge; 50% of these chil-
dren were readmitted within 8 days of discharge and 77%
were readmitted within 21 days of discharge. Twenty-four
percent of patients who were admitted for short-stay ad-
missions and discharged after 24 hours were readmitted.14
Research in the literature review supports the importance
of adult SCD patients having access to comprehensive spe-
cialty care run by a principal health care provider and an
experienced team of health care professionals, both medical
and nonmedical, who are knowledgeable about SCD man-
agement and treatment.
Methods
Practice design and methodology
The researcher (NA) used quantitative exploratory analy-
sis and descriptive statistics to determine relationships be-
tween the variables selected: age, insurance type, patient zip
code of residence, patient county of residence, number of
hospital admissions, number of hospital readmissions within
7 and 30 days, hospital costs, LOS, total acute care costs, and
International Classification of Diseases, Ninth Revision (ICD-9)
codes for visits at 3 local hospitals in order to obtain a de-
scriptive picture of acute care utilization services for adults
with SCD in Delaware from 2007 to 2009. De-identified data
were extracted from Delaware hospital discharge records
stored at the Office of Vital Statistics and sorted from a se-
cured zip file with permission from the Delaware Depart-
ment of Health and Social Services (DHSS) and Thomas
Jefferson University’s Institutional Review Board.
Inclusion and exclusion criteria
Inclusion criteria were adult residents with SCD who re-
ceived acute care at 1 small community hospital and 1 large
community hospital system from 2007 to 2009. Exclusion
criteria were patients younger than 18 years of age with no
ICD-9 code associated with SCD who were admitted to a
Sussex County hospital and a large pediatric hospital in
Delaware.
Acute care utilization for SCD was extracted from com-
pulsory hospital discharge data that Delaware hospitals re-
port to the DHSS Office of Vital Statistics (Delaware
Department of Health and Social Services, unpublished data,
2012). Data were abstracted from 1 community hospital and
2 hospital systems located in New Castle and Kent Counties
because 90% SCD of patients resided in these counties.
Therefore, it was presumed that adult SCD patients utilized
hospitals in these counties for their acute SCD needs. The
data included adults aged 18 years and older at admission
with a primary or secondary diagnose(s) of SCD and who
resided in Delaware. The patient’s sex, hydroxyurea use,
SCD genotype, and data from ER visits not resulting in in-
patient admission were not accessible to the researcher.
Statistical analysis
Frequencies were run on the following variables: age, in-
surance type, zip code, county, primary ICD-9 code, hospital
costs, LOS, readmissions, and visits for analysis. Descriptive
statistics were run on age, LOS, and hospital costs to deter-
mine the distribution of the data. Crosstabs were run to
compare all variables within each data set to determine
relationships between and among variables. Notable findings
included: 86% of adult SCD acute care hospital visits were
billed to public insurers, 75% of acute care visits were in New
Castle County, and 69% utilized City-Suburban Health Sys-
tem. Overall, publicly insured adult SCD patients had longer
hospital LOS than privately insured adult SCD patients.
Results
There were 518 acute care episodes from 2007 to 2009
(Table 1). The most recent and complete data set provided
was in 2009; this was analyzed along with the trends from
previous years.
Results from 2009 data show that there were 96 discrete
adult SCD patients in the data sets, totalling 202 hospital
visits in 2009. Utilization data for 2007–2009 are shown in
Table 1. The 202 adult SCD patients had more hospital visits
in New Castle County (140/202) than in Kent County
(62/202).
Table 1. DHSS Acute Care Utilization
Data Set 2007–2009
Year
2007 2008 2009
Visits 151 165 202
Mean Costs per
inpatient stay
$14,940 $14,584 $16,287
Median Costs $10,291 $9,732 $11,218
Mean age 32.3 years 34.9 years 32.5 years
Median 30 years 33 years 31 years
Mean LOS 7.9 days 6.6 days 6.7 days
Median 5 days 5 days 5 days
Readmit within
30 days
38 44 66
Readmit within
7 days
8 12 23
Total Charges $2.3 million $2.4 million $3.3 million
DHSS, Department of Health and Social Services; LOS, length of
stay.
Table 2. DHSS Hospital Acute Care
Data Set 2007–2009
City-
Suburban
Suburban-
Rural City
County New Castle Kent New Castle
Visits 357 119 42
Mean Costs $15,724 $14,912 $13,431
Median Costs $10,823 $10,633 $9,460
Mean LOS 7.8 days 5.6 days 4.6 days
Median LOS 6 days 4 days 3 days
Readmit w/n
30 days
104 32 12
Readmit w/n
7 days
26 12 5
Total Costs $5.6 million $1.8 million $564,124
Hospitals in Sussex County were not analyzed.
DHSS, Department of Health and Social Services; LOS, length of
stay.
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The minimum cost of SCD acute care utilization reported
in the data set was $1800 (LOS 1 day) and the maximum
acute care utilization cost was $137,073 (LOS 43 days). The
data showed that 84% of patients with acute care visits were
publicly insured, 47% by Medicaid (94/202) and 37% by
Medicare (75/202); 11% of patients with acute care visits
carried private insurance coverage and 5% were uninsured.
Secondary insurance type, if applicable, could not be deter-
mined from the data provided. It was found that 99.5% visits
were ICD-9 coded for vaso-occlusive crisis as the primary
diagnosis for the hospital visit. The 7-day rehospitalization
rate was 11% and 30-day rehospitalization rate in 2009 was
33% and for SCD-related causes (Table 2).
From 2007 to 2009, there was a 24% increase in Medicaid
insured acute care visits and a 10% increase in uninsured
visits. Although there was a small percentage of patients with
private insurance, there was a 50% increase in acute care
visits. The mean inpatient hospital cost per year for an adult
SCD patient increased 8.3% from 2007 to 2009; median costs
increased by the same percentage for the same time period
(Table 1). Mean inpatient LOS decreased 15% from 2007 to
2009, while median LOS stayed the same for the same time
frame (Table 1). The highest hospital costs were $244,861, paid
by Medicaid, for a 62-year-old patient whose LOS was 105
days in 2007. Acute care utilization for adults with SCD tri-
pled in Kent County from 2007 to 2009 (13/151 to 53/202).
The adult SCD patients who utilized hospitals from 2007 to
2009 lived in New Castle County, (389/518), Kent County
(93/518), and Sussex County (36/518) (Table 2).
Comparison of data to other geographic areas
Comparing Delaware SCD data to national and other
states’ total hospital costs, LOS, and hospital cost averages
was a challenge (Table 3). Each data set defined variables
differently, which presented a challenge to pure data com-
parison. Neither the HCUP nor the Connecticut study re-
ported yearly mean or median hospital costs, except for total
hospital visit cost.15 It can be concluded that there needs to be
better standardized methodology to determine hospital costs
for adult SCD inpatient hospital care; therefore, it is difficult to
make accurate comparisons for acute care hospital costs.
Discussion
In light of the findings, characteristics of acute care utili-
zation for adult SCD patients in Delaware found that acute
care hospital inpatient costs are steadily rising, which is re-
flective of national trends. Hospital readmissions within 7
and 30 days also have increased, but hospital LOS for acute
care visits has remained fairly constant. Moreover, HCUP
has found that over 75% of hospital visits for SCD nation-
wide were billed to public insurers.7 The majority (82.4%) of
adult SCD patients who resided in the state of Delaware in
2009 were publicly insured and 4.8% were uninsured, which
is slightly higher when benchmarking against data from
HCUP (Delaware Department of Health and Social Services,
unpublished data, 2012). Therefore, the majority of adults
with SCD rely on public health insurance plans for their
medical care, which are funded with public taxpayer dollars.
Readmissions
Reducing hospital readmission rates has attracted the at-
tention of public policymakers to develop a plan of action to
improve the quality of health care delivery in the hospital
while containing Medicare costs. The Medicare Payment
Advisory Commission (MedPAC) mandates that hospitals
with high risk-adjusted rehospitalization rates receive lower
payments for preventable hospital readmissions. MedPAC
reported that Mediare expenditures for potentially prevent-
able rehospitalizations may be as high as $12 billion a year. A
study of SCD hospitalizations in a geographically dispersed
area found 30-day rehospitalization rates to be 33% for all
ages.13 In Delaware in 2009, the 7-day rehospitalization rate
was 11% and the 30-day rehospitalization rate was 33%.
Costs
Delaware’s adult SCD acute care median hospital costs
and LOS were lower than the mean hospital costs and LOS
because data distribution of median hospital costs was more
symmetric and less skewed. Therefore, the median hospital
costs were a more accurate comparison of SCD acute care
utilization in Delaware (Fig. 1). With evidence that Delaware
SCD costs increased almost 10% from 2007 to 2009, inpatient
Table 3. Comparison of Adult SCD Hospital Inpatient Care
Delaware Connecticut1 National2 PA Hospital3
2009 2005 2004 2005
Visits 202 Not reported 83,149 (2004) 1540
Adults Adults Adults & Children Adult
Mean Costs $16,287 Not reported Not reported Not reported
Median $11,218
Mean LOS 6.7 days 8.7 days 5.5 days 7.6 days
Median 5 days
Readmit w/n 30 days 33% Not reported Not reported *50% SS-type
Readmit w/n 7 days 11% Not reported Not reported *16%SS-type
Hospital Total Costs $3.3 million $10.7 million $488 million Not reported
1The average length of stay (LOS) and data were taken from the Connecticut Health Information Exchange Data (CHIME) for inpatient
admissions, hospital-based ambulatory surgery, and emergency department visits for all thirty (30) of Connecticut’s acute care hospitals.18
2The national Healthcare Cost and Utilization Project (HCUP) data for SCD patient characteristics, costs of hospital stays, and outcomes
from 1994–2004.9
3The PA Hospital data was taken from American Journal of Hematology.14
LOS, length of stay; SCD, sickle cell disease.
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LOS had less change, respectively. Further analysis of hos-
pital costs for outlier patients on the higher end of the dis-
tribution curve who positively skewed the data may better
explain the differences between the mean and median costs.
In this study, the high percentage (99.5%) of hospital ad-
missions from the ER for vaso-occlusive crisis further
demonstrates that there is a need for more integrated, coor-
dinated care services that can provide transitional care
services to reduce hospital readmissions and increase access
to a statewide community-based comprehensive specialty
care.2,13,19 Access to disease modifying therapies, such as
hydroxyurea utilization, are facilitated by access to com-
prehensive specialty SCD care clinics. Hydroxyurea has been
shown to reduce hospital admission rates by 40%–50% in
adult SCD patients who respond to the medication.16–18
Limitations
Observation of the data sets found positive skewness and
kurtosis in the asymmetry of distribution of the total charges
and LOS; therefore, the mean total charges and LOS were
40%–50% higher than the median (Fig. 1). This may indicate
that further study is needed to analyze high SCD acute care
patient utilization patterns and their access to disease mod-
ifying therapies such as hydroxyurea. The age variable in the
data set was more evenly distributed and only slightly
skewed. Data were not available to determine the costs for
ER visits for patients discharged to home, prescription costs,
hydroxyurea usage, transportation costs, and visits in the
outpatient setting (ambulatory care and physician visits).
The HCUP sampling frame was limited to 90% of all hospital
discharges in the United States, and coding errors may have
increased the overall SCD costs in the hospital stay data.7
Further exploration of these costs will determine total health
care costs and LOS more effectively for SCD adult care in
Delaware. Those costs can then be benchmarked against
national findings in a more pure data set comparison; cur-
rently, each data set defined variables differently.
Conclusion
Overall, the cost of acute care utilization for SCD vaso-
occlusive episodes is increasing in the adult SCD population.
There is an urgent need to reduce health care costs and increase
access to high-quality care, especially for socioeconomically
disadvantaged and vulnerable patient populations. The state of
FIG. 1. Data distribution for total hospital costs.
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Delaware would benefit from an adequately resourced, inte-
grated, statewide community-based adult SCD comprehensive
specialty program to increase patient access to high-quality care
and reduce health care costs. Overall, the future of SCD
awareness, treatment, management, and research remains un-
certain; however, increasing acute care costs for adults with SCD
pose a significant taxpayer burden as the cost of health care
continues to rise.
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